|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2005
Exhaled nitric oxide from lung periphery is increased in COPD
1 Section of Airway Disease, National Heart and Lung Institute, Imperial College, London, UK. 2 Institute of Respiratory Disease, University of Bari, Bari, Italy.
CORRESPONDENCE: S. A. Kharitonov, Section of Airway Disease, National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK. Fax: +44 2073518126. E-mail: s.kharitonov@imperial.ac.uk
Keywords: Chronic obstructive pulmonary disease, exhaled nitric oxide, multiple expiratory flow, small airway inflammation
Received: November 1, 2004
Accepted March 26, 2005
Single constant flow exhaled nitric oxide (eNO) cannot distinguish between the sources of NO. The present study measured eNO at multiple expired flows (MEFeNO) to partition NO into alveolar (Calv,NO) and bronchial (Jaw,NO) fractions to investigate peripheral lung contribution to eNO in chronic obstructive lung disease (COPD).
MEFeNO were made in 81 subjects including 18 nonsmokers, 16 smokers and 47 COPD patients of different severity by the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD): 0 (n = 14), 1 (n = 7), 2 (n = 11), 3 (n = 8) and 4 (n = 7).
COPD severity was correlated with an increased Calv,NO regardless of the patient's smoking habit or current treatment. The levels of Calv,NO (in ppb) were 1.4±0.09 in nonsmokers, 2.1±0.1 in smokers categorised as GOLD stage 0 (smokers-GOLD0), 3.3±0.18 in GOLD1–2 and 3.4±0.1 in GOLD3–4. Jaw,NO levels (pL·s–1) were higher in nonsmokers than smokers-GOLD0 (716.2±33.3 versus 464.7±41.8), GOLD3–4 (609.4±71). Diffusion of NO in the airways (Daw,NO pL·ppb–1s–1) was higher (p<0.05) in GOLD3–4 than in nonsmokers (15±1.2 versus 11±0.5) and smokers-GOLD0 (11.6±0.5). MEFeNO measurements were reproducible, free from day-to-day and diurnal variation and were not affected by bronchodilators.
In conclusion, chronic obstructive pulmonary disease is associated with elevated alveolar nitric oxide. Measurements of nitric oxide at multiple expired flows may be useful in monitoring inflammation and progression of chronic obstructive pulmonary disease, and the response to anti-inflammatory treatment.
This article has been cited by other articles:
|
|
 |
|
  P. J. Barnes Histone deacetylase-2 and airway disease Therapeutic Advances in Respiratory Disease, October 1, 2009; 3(5): 235 - 243. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Nakamaru, C. Vuppusetty, H. Wada, J. C. Milne, M. Ito, C. Rossios, M. Elliot, J. Hogg, S. Kharitonov, H. Goto, et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9 FASEB J, September 1, 2009; 23(9): 2810 - 2819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. O. Osoata, T. Hanazawa, C. Brindicci, M. Ito, P. J. Barnes, S. Kharitonov, and K. Ito Peroxynitrite Elevation in Exhaled Breath Condensate of COPD and Its Inhibition by Fudosteine Chest, June 1, 2009; 135(6): 1513 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Brindicci, K. Ito, O. Torre, P. J. Barnes, and S. A. Kharitonov Effects of Aminoguanidine, an Inhibitor of Inducible Nitric Oxide Synthase, on Nitric Oxide Production and Its Metabolites in Healthy Control Subjects, Healthy Smokers, and COPD Patients Chest, February 1, 2009; 135(2): 353 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D R Taylor and I D Pavord Biomarkers in the assessment and management of airways diseases Postgrad. Med. J., December 1, 2008; 84(998): 628 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Barregard, G Sallsten, L Andersson, A-C Almstrand, P Gustafson, M Andersson, and A-C Olin Experimental exposure to wood smoke: effects on airway inflammation and oxidative stress Occup. Environ. Med., May 1, 2008; 65(5): 319 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Foresi, C. Leone, D. Olivieri, and G. Cremona Alveolar-Derived Exhaled Nitric Oxide Is Reduced in Obstructive Sleep Apnea Syndrome Chest, September 1, 2007; 132(3): 860 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Brindicci, K. Ito, P. J. Barnes, and S. A. Kharitonov Effect of an Inducible Nitric Oxide Synthase Inhibitor on Differential Flow-Exhaled Nitric Oxide in Asthmatic Patients and Healthy Volunteers Chest, August 1, 2007; 132(2): 581 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lehtonen, P. Oksa, L. Lehtimaki, A. Sepponen, R. Nieminen, H. Kankaanranta, S. Saarelainen, R. Jarvenpaa, J. Uitti, and E. Moilanen Increased alveolar nitric oxide concentration and high levels of leukotriene B4 and 8-isoprostane in exhaled breath condensate in patients with asbestosis Thorax, July 1, 2007; 62(7): 602 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli and P. J. Barnes Exacerbations of chronic obstructive pulmonary disease Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Brindicci, K. Ito, P. J. Barnes, and S. A. Kharitonov Differential Flow Analysis of Exhaled Nitric Oxide in Patients With Asthma of Differing Severity Chest, May 1, 2007; 131(5): 1353 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Roy, Z. L. Borrill, C. Starkey, A. L. Hazel, J. Morris, J. Vestbo, and D. Singh Use of different exhaled nitric oxide multiple flow rate models in COPD Eur. Respir. J., April 1, 2007; 29(4): 651 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Birrell, K. McCluskie, E. Hardaker, R. Knowles, and M. G. Belvisi Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model Eur. Respir. J., December 1, 2006; 28(6): 1236 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Kharitonov and P. J. Barnes Exhaled biomarkers. Chest, November 1, 2006; 130(5): 1541 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D R Taylor, M W Pijnenburg, A D Smith, and J C D Jongste Exhaled nitric oxide measurements: clinical application and interpretation Thorax, September 1, 2006; 61(9): 817 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes, B. Chowdhury, S. A. Kharitonov, H. Magnussen, C. P. Page, D. Postma, and M. Saetta Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 6 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes Reduced Histone Deacetylase in COPD: Clinical Implications Chest, January 1, 2006; 129(1): 151 - 155. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |